October 30, 2020 Conference
High Risk PDR: Anti-VEGF or PRP?
Return to Session
Dr. Caroline Baumal, NEEC New England Eye Center (Presenter)
Panretinal laser photocoagulation (PRP) has been the main treatment of proliferative diabetic retinopathy (PDR) for over 40 years. However, recent findings from protocol S and other studies demonstrate that anti-VEGF intravitreal injection may be an alternative treatment. The DRCR.net protocol S compared anti-VEGF injection to PRP laser for treatment of PDR. The 5 year study results demonstrated that overall both treatments performed well. Specific retinal factors such as the presence of diabetic macular edema or vitreous hemorrhage may favor anti-VEGF injections, while patients who are not available for frequent office visits may be more suitable for PRP. These issues and cases will be reviewed.